Zhejiang Orient Gene Biotech Co (SHSE:688298) Piotroski F-Score: 5 (As of Jul. 26, 2026) — 25% Above Median

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SHSE:688298 Zhejiang Orient Gene Biotech Co Ltd SHSE:688298
51 GF Score
Price ¥17.87
GF Value ¥30.81
Valuation Possible Value Trap
! 2 Warning Signs
View Full Analysis

What is Zhejiang Orient Gene Biotech Co Piotroski F-Score?

Zhejiang Orient Gene Biotech Co SHSE:688298 -3.51% 51 Piotroski F-Score is 5 as of Jul. 26, 2026, which is 25% above its 10-year median of 4.00. GuruFocus rates SHSE:688298 with a GF Score™ of 51/100 and a GF Value™ of ¥30.81 (Possible Value Trap). The stock has 2 warning signs investors should review. Among 802 Medical Devices & Instruments companies, Zhejiang Orient Gene Biotech Co ranks better than 64.59% on this metric.

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Zhejiang Orient Gene Biotech Co has an F-score of 5 indicating the company's financial situation is typical for a stable company.

The historical rank and industry rank for Zhejiang Orient Gene Biotech Co's Piotroski F-Score or its related term are showing as below:

SHSE:688298' s Piotroski F-Score Range Over the Past 10 Years
Min: 1   Med: 4   Max: 8
Current: 5

During the past 10 years, the highest Piotroski F-Score of Zhejiang Orient Gene Biotech Co was 8. The lowest was 1. And the median was 4.

Zhejiang Orient Gene Biotech Co  (SHSE:688298) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


Zhejiang Orient Gene Biotech Co Piotroski F-Score Related Terms


Zhejiang Orient Gene Biotech Co Piotroski F-Score Historical Data

* Premium members only.

The historical data trend for Zhejiang Orient Gene Biotech Co's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Zhejiang Orient Gene Biotech Co Piotroski F-Score Chart

Zhejiang Orient Gene Biotech Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Piotroski F-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only 5.00 3.00 1.00 4.00 5.00

Zhejiang Orient Gene Biotech Co Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Piotroski F-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.00 4.00 5.00 5.00 5.00

SHSE:688298 vs ABT, SYK, MDT: Piotroski F-Score Comparison

For the Medical Devices subindustry, Zhejiang Orient Gene Biotech Co's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Zhejiang Orient Gene Biotech Co Piotroski F-Score vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Zhejiang Orient Gene Biotech Co's Piotroski F-Score distribution charts can be found below:

* The bar in red indicates where Zhejiang Orient Gene Biotech Co's Piotroski F-Score falls into.


SHSE:688298
51GF Score
Zhejiang Orient Gene Biotech Co Ltd SHSE:688298
Piotroski F-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Mar26) TTM:Last Year (Mar25) TTM:
Net Income was -47.645 + -49.534 + -360.966 + -93.843 = ¥-552 Mil.
Cash Flow from Operations was -68.982 + -31.362 + -39.266 + -29.109 = ¥-169 Mil.
Revenue was 211.128 + 268.732 + 275.568 + 256.265 = ¥1,012 Mil.
Gross Profit was 99.117 + 128.088 + 106.757 + 109.922 = ¥444 Mil.
Average Total Assets from the begining of this year (Mar25)
to the end of this year (Mar26) was
(7759.162 + 7610.621 + 7507.724 + 7138.946 + 6893.051) / 5 = ¥7381.9008 Mil.
Total Assets at the begining of this year (Mar25) was ¥7,759 Mil.
Long-Term Debt & Capital Lease Obligation was ¥70 Mil.
Total Current Assets was ¥3,038 Mil.
Total Current Liabilities was ¥802 Mil.
Net Income was -84.254 + -110.549 + -266.867 + -115.452 = ¥-577 Mil.

Revenue was 235.313 + 239.379 + 170.302 + 191.952 = ¥837 Mil.
Gross Profit was 89.757 + 79.2 + 34.652 + 52.518 = ¥256 Mil.
Average Total Assets from the begining of last year (Mar24)
to the end of last year (Mar25) was
(8759.354 + 8442.943 + 8234.404 + 8094.58 + 7759.162) / 5 = ¥8258.0886 Mil.
Total Assets at the begining of last year (Mar24) was ¥8,759 Mil.
Long-Term Debt & Capital Lease Obligation was ¥156 Mil.
Total Current Assets was ¥3,584 Mil.
Total Current Liabilities was ¥887 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Zhejiang Orient Gene Biotech Co's current Net Income (TTM) was -552. ==> Negative ==> Score 0.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Zhejiang Orient Gene Biotech Co's current Cash Flow from Operations (TTM) was -169. ==> Negative ==> Score 0.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Mar25)
=-551.988/7759.162
=-0.07114016

ROA (Last Year)=Net Income/Total Assets (Mar24)
=-577.122/8759.354
=-0.06588637

Zhejiang Orient Gene Biotech Co's return on assets of this year was -0.07114016. Zhejiang Orient Gene Biotech Co's return on assets of last year was -0.06588637. ==> Last year is higher ==> Score 0.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

Zhejiang Orient Gene Biotech Co's current Net Income (TTM) was -552. Zhejiang Orient Gene Biotech Co's current Cash Flow from Operations (TTM) was -169. ==> -169 > -552 ==> CFROA > ROA ==> Score 1.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Mar26)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Mar25 to Mar26
=69.696/7381.9008
=0.00944147

Gearing (Last Year: Mar25)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Mar24 to Mar25
=155.632/8258.0886
=0.01884601

Zhejiang Orient Gene Biotech Co's gearing of this year was 0.00944147. Zhejiang Orient Gene Biotech Co's gearing of last year was 0.01884601. ==> This year is lower or equal to last year. ==> Score 1.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Mar26)=Total Current Assets/Total Current Liabilities
=3038.343/802.319
=3.78695132

Current Ratio (Last Year: Mar25)=Total Current Assets/Total Current Liabilities
=3583.909/886.725
=4.04173673

Zhejiang Orient Gene Biotech Co's current ratio of this year was 3.78695132. Zhejiang Orient Gene Biotech Co's current ratio of last year was 4.04173673. ==> Last year's current ratio is higher ==> Score 0.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

Zhejiang Orient Gene Biotech Co's number of shares in issue this year was 191.517. Zhejiang Orient Gene Biotech Co's number of shares in issue last year was 202.548. ==> There is smaller number of shares in issue this year, or the same. ==> Score 1.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=443.884/1011.693
=0.43875365

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=256.127/836.946
=0.30602572

Zhejiang Orient Gene Biotech Co's gross margin of this year was 0.43875365. Zhejiang Orient Gene Biotech Co's gross margin of last year was 0.30602572. ==> This year's gross margin is higher. ==> Score 1.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Mar25)
=1011.693/7759.162
=0.13038689

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Mar24)
=836.946/8759.354
=0.09554883

Zhejiang Orient Gene Biotech Co's asset turnover of this year was 0.13038689. Zhejiang Orient Gene Biotech Co's asset turnover of last year was 0.09554883. ==> This year's asset turnover is higher. ==> Score 1.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=0+0+0+1+1+0+1+1+1
=5

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Zhejiang Orient Gene Biotech Co has an F-score of 5 indicating the company's financial situation is typical for a stable company.

Frequently Asked Questions Learn more about Piotroski F-Score →
What does a Piotroski F-Score of 5 mean?
Zhejiang Orient Gene Biotech Co (SHSE:688298) has a Piotroski F-Score of 5 as of Jul. 26, 2026. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Zhejiang Orient Gene Biotech Co and its competitors. This is 25% above median its historical median of 4.00. Over the past decade, Zhejiang Orient Gene Biotech Co's Piotroski F-Score has ranged from 1.00 to 8.00. According to the industry distribution chart, Zhejiang Orient Gene Biotech Co ranks #284 out of 802 companies in the Medical Devices & Instruments industry, placing it in the top 35.4%.
Is Zhejiang Orient Gene Biotech Co's Piotroski F-Score too high?
Zhejiang Orient Gene Biotech Co's current Piotroski F-Score of 5 is 25% above median its 10-year median of 4.00. Over the past 10 years, this metric has ranged from a low of 1.00 to a high of 8.00. The Medical Devices & Instruments industry median Piotroski F-Score is 5.00. Zhejiang Orient Gene Biotech Co's value of 5 is 0% at this industry median. Based on the distribution chart, Zhejiang Orient Gene Biotech Co ranks #284 out of 802 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Zhejiang Orient Gene Biotech Co has a GF Score™ of 51/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Zhejiang Orient Gene Biotech Co's Piotroski F-Score compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Zhejiang Orient Gene Biotech Co ranks #284 out of 802 companies for Piotroski F-Score. This puts Zhejiang Orient Gene Biotech Co in the upper half of its industry. The industry median Piotroski F-Score is 5.00. Zhejiang Orient Gene Biotech Co's value of 5 is 0% at this benchmark. Historically, Zhejiang Orient Gene Biotech Co's own Piotroski F-Score has ranged from 1.00 to 8.00 over the past decade. While the company's 10-year median is 4.00 vs. the industry median of 5.00, Zhejiang Orient Gene Biotech Co has consistently been at the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Piotroski F-Score for a Medical Devices & Instruments company?
The median Piotroski F-Score among Medical Devices & Instruments companies is 5.00, based on 802 companies in the industry. Companies in the top quartile (top 25%) have a Piotroski F-Score significantly above this median, while those in the bottom quartile fall well below. However, Piotroski F-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Zhejiang Orient Gene Biotech Co's current Piotroski F-Score of 5 is 0% at the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Piotroski F-Score mean?
A high Piotroski F-Score can signal that a stock is expensive relative to its fundamentals. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Zhejiang Orient Gene Biotech Co and its competitors. For the Medical Devices & Instruments industry, the median Piotroski F-Score is 5.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Zhejiang Orient Gene Biotech Co's current Piotroski F-Score is 5, which is 25% above median its own 10-year median of 4.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zhejiang Orient Gene Biotech Co stock overvalued right now?
Based on GuruFocus' analysis, Zhejiang Orient Gene Biotech Co (SHSE:688298) is currently considered Possible Value Trap. The stock's GF Value™ is ¥30.81, compared to a current price of ¥17.87 — trading 42% below its estimated fair value. The current Piotroski F-Score is 5, which is 25% above median its 10-year median of 4.00 and 0% at the Medical Devices & Instruments industry median of 5.00. Zhejiang Orient Gene Biotech Co's overall GF Score™ is 51/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Piotroski F-Score calculated?
Piotroski F-Score is calculated from a company's financial statements. For Zhejiang Orient Gene Biotech Co (SHSE:688298), the current Piotroski F-Score is 5 as of Jul. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Zhejiang Orient Gene Biotech Co (SHSE:688298) Overvalued in 2026?

Based on GuruFocus' analysis, Zhejiang Orient Gene Biotech Co stock appears to be undervalued. The current stock price of ¥17.87 is trading 42% below its estimated GF Value™ of ¥30.81. GuruFocus considers Zhejiang Orient Gene Biotech Co to be Possible Value Trap.

Key valuation signals for SHSE:688298:

  • Piotroski F-Score: 5 (25% above median its 10-year median of 4.00)
  • GF Value™: ¥30.81 vs. price of ¥17.87 (42% below fair value)
  • GF Score™: 51/100 with 2 warning signs
  • Industry Position: 0% at the Medical Devices & Instruments median (#284 of 802)

No single metric tells the full story. See the SHSE:688298 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Zhejiang Orient Gene Biotech Co Business Description

Address 3787 East Section of Yangguang Avenue, Dipu Street, Anji County, Zhejiang Province, Huzhou, CHN, 313300
Zhejiang Orient Gene Biotech Co Ltd is engaged in production, research, development and sale of vitro diagnostic products. The company's products include Genetic diagnosis, Colloidal gold rapid diagnostic tests, Dry chemical strips (urinalysis), Bio-liquid diagnostic kits, Clinical test instruments, POCT time-resolved Fluor immunoassay Test kit (TRFI), and Raw materials.
51GF Score

Get the complete analysis for SHSE:688298

Piotroski F-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

¥17.87
Price
¥30.81
GF Value